These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. Zhao Z; Condomines M; van der Stegen SJC; Perna F; Kloss CC; Gunset G; Plotkin J; Sadelain M Cancer Cell; 2015 Oct; 28(4):415-428. PubMed ID: 26461090 [TBL] [Abstract][Full Text] [Related]
13. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. Guedan S; Posey AD; Shaw C; Wing A; Da T; Patel PR; McGettigan SE; Casado-Medrano V; Kawalekar OU; Uribe-Herranz M; Song D; Melenhorst JJ; Lacey SF; Scholler J; Keith B; Young RM; June CH JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321369 [TBL] [Abstract][Full Text] [Related]
14. Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen. Shirasu N; Shibaguci H; Kuroki M; Yamada H; Kuroki M Anticancer Res; 2010 Jul; 30(7):2731-8. PubMed ID: 20683006 [TBL] [Abstract][Full Text] [Related]
15. Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer. Hombach AA; Abken H Immunotherapy; 2013 Jul; 5(7):677-81. PubMed ID: 23829616 [No Abstract] [Full Text] [Related]
16. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack. Chmielewski M; Hombach AA; Abken H Gene Ther; 2011 Jan; 18(1):62-72. PubMed ID: 20944680 [TBL] [Abstract][Full Text] [Related]
17. Transgene-enforced co-stimulation of CD4+ T cells leads to enhanced and sustained anti-tumor effector functioning. Chang L; Chang WC; McNamara G; Aguilar B; Ostberg JR; Jensen MC Cytotherapy; 2007; 9(8):771-84. PubMed ID: 17917884 [TBL] [Abstract][Full Text] [Related]
18. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Maus MV; Thomas AK; Leonard DG; Allman D; Addya K; Schlienger K; Riley JL; June CH Nat Biotechnol; 2002 Feb; 20(2):143-8. PubMed ID: 11821859 [TBL] [Abstract][Full Text] [Related]
19. Aptamer-Targeted Attenuation of IL-2 Signaling in CD8 Rajagopalan A; Berezhnoy A; Schrand B; Puplampu-Dove Y; Gilboa E Mol Ther; 2017 Jan; 25(1):54-61. PubMed ID: 28129128 [TBL] [Abstract][Full Text] [Related]
20. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy. Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]